Literature DB >> 2023111

An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

D B White1, C A Walawander, Y Tung, T H Grasela.   

Abstract

In a simulation study of the estimation of population pharmacokinetic parameters, including fixed and random effects, the estimates and confidence intervals produced by NONMEM were evaluated. Data were simulated according to a monoexponential model with a wide range of design and statistical parameters, under both steady state (SS) and non-SS conditions. Within the range of values for population parameters commonly encountered in research and clinical settings, NONMEM produced parameter estimates for CL, V, sigma CL, and sigma epsilon which exhibit relatively small biases. As the range of variability increases, these biases became larger and more variable. An important exception was bias in the estimate for sigma V which was large even when the underlying variability was small. NONMEM standard error estimates are appropriate as estimates of standard deviation when the underlying variability is small. Except in the case of CL, standard error estimates tend to deteriorate as underlying variability increases. An examination of confidence interval coverage indicates that caution should be exercised when the usual 95% confidence intervals are used for hypothesis testing. Finally, simulation-based corrections of point and interval estimates are possible but corrections must be performed on a case-by-case basis.

Mesh:

Year:  1991        PMID: 2023111     DOI: 10.1007/bf01062194

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  18 in total

1.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients.

Authors:  P O Maitre; S Vozeh; J Heykants; D A Thomson; D R Stanski
Journal:  Anesthesiology       Date:  1987-01       Impact factor: 7.892

3.  The population pharmacokinetics of theophylline in neonates and young infants.

Authors:  E S Moore; R G Faix; R C Banagale; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

4.  An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.

Authors:  T H Grasela; E J Antal; L Ereshefsky; B G Wells; R L Evans; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

5.  A note on confidence intervals with extended least squares parameter estimates.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

6.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

7.  Experience with NONMEM: analysis of serum concentration data in patients treated with mexiletine and lidocaine.

Authors:  S Vozeh; M Wenk; F Follath
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

8.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

9.  Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.

Authors:  R B Smith; P D Kroboth; J T Vanderlugt; J P Phillips; R P Juhl
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  17 in total

1.  Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.

Authors:  A J Jackson; L A Ouderkirk
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

4.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

5.  Response to "An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis" by White et al.

Authors:  K F Phillips
Journal:  J Pharmacokinet Biopharm       Date:  1992-08

6.  Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Authors:  Paul G Baverel; Radojka M Savic; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-13       Impact factor: 2.745

7.  The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.

Authors:  Maria C Kjellsson; Siv Jönsson; Mats O Karlsson
Journal:  AAPS J       Date:  2004-08-11       Impact factor: 4.009

Review 8.  Pharmacodynamic parameter estimation: population size versus number of samples.

Authors:  Suzette Girgis; Sudhakar M Pai; Ihab G Girgis; Vijay K Batra
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 9.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

10.  Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates.

Authors:  Sudhakar M Pai; Suzette Girgis; Vijay K Batra; Ihab G Girgis
Journal:  AAPS J       Date:  2009-07-24       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.